Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

References

• American Diabetes Association Standards of medical care in diabetes – 2014 Diabetes Care 2014 37 Suppl 1 S14 S80 24357209
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement Endocr Pract 2013 19 Suppl 2 1 48 24129260
   PubMed Web of Science ®Google Scholar
• Pratley RE Kipnes MS Fleck PR Wilson C Mekki Q Alogliptin Study 007 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy Diabetes Obes Metab 2009 11 2 167 176 19125778
   PubMed Web of Science ®Google Scholar
• Rosenstock J Rendell MS Gross JL Fleck PR Wilson CA Mekki Q Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia Diabetes Obes Metab 2009 11 12 1145 1152 19758359
   PubMed Web of Science ®Google Scholar
• Nauck MA Homberger E Siegel EG Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 1986 63 2 492 498 3522621
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Mentis N Vardarli I Köthe LD GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes Diabetes 2011 60 4 1270 1276 21330636
   PubMed Web of Science ®Google Scholar
• Covington P Christopher R Davenport M Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes Clin Ther 2008 30 3 499 512 18405788
   PubMed Web of Science ®Google Scholar
• Nauck MA Niedereichholz U Ettler R Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 1997 273 5 Pt 1 E981 E988 9374685
   PubMed Web of Science ®Google Scholar
• Nauck MA Heimesaat MM Orskov C Holst JJ Ebert R Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 1993 91 1 301 307 8423228
   PubMed Web of Science ®Google Scholar
• Baetta R Corsini A Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences Drugs 2011 71 11 1441 1467 21812507
   PubMed Web of Science ®Google Scholar
• Golightly LK Drayna CC McDermott MT Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors Clin Pharmacokinet 2012 51 8 501 514 22686547
   PubMed Web of Science ®Google Scholar
• Christopher R Covington P Davenport M Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects Clin Ther 2008 30 3 513 527 18405789
   PubMed Web of Science ®Google Scholar
• Scott LJ Alogliptin: a review of its use in the management of type 2 diabetes mellitus Drugs 2010 70 15 2051 2072 20883057
   PubMed Web of Science ®Google Scholar
• Nauck MA A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks Diabetes Care 2013 36 7 2126 2132 23645884
   PubMed Web of Science ®Google Scholar
• Scheen AJ Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions Clin Pharmacokinet 2010 49 9 573 588 20690781
   PubMed Web of Science ®Google Scholar
• Karim A Fleck P Dorsey D Zhang W Mekki Q Preston RA Single dose pharmacokinetics of alogliptin benzoate(SYR-322) in subjects with moderate hepatic impairment: Thirty - Sixth Annual Meeting American College of Clinical Pharmacology, San Francisco, CA, USA, 9–11 September 2007 J Clin Pharmacol 2007 47 9 1207
   Web of Science ®Google Scholar
• Karim A Fleck P Harrell RE Effects of age, race, and gender on the pharmacokinetics and pharmacodynamics of alogliptin, a novel and highly selective dipeptidyl peptidase-4 inhibitor, in healthy subjects Clin Pharmacol Ther 2008 83 Suppl 1 PI-14
   Google Scholar
• Karim A Covington P Christopher R Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects Int J Clin Pharmacol Ther 2010 48 1 46 58 20040339
   PubMed Web of Science ®Google Scholar
• Nauck MA Ellis GC Fleck PR Wilson CA Mekki Q Alogliptin Study 008 Group Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study Int J Clin Pract 2009 63 1 46 55 19125992
   PubMed Web of Science ®Google Scholar
• Seino Y Miyata Y Hiroi S Hirayama M Kaku K Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study Diabetes Obes Metab 2012 14 10 927 936 22583697
   PubMed Web of Science ®Google Scholar
• Rosenstock J Inzucchi SE Seufert J Fleck PR Wilson CA Mekki Q Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes Diabetes Care 2010 33 11 2406 2408 20724648
   PubMed Web of Science ®Google Scholar
• Kaku K Itayasu T Hiroi S Hirayama M Seino Y Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study Diabetes Obes Metab 2011 13 11 1028 1035 21682833
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Burant CF Fleck P Wilson C Mekki Q Pratley RE Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes J Clin Endocrinol Metab 2012 97 5 1615 1622 22419732
   PubMed Web of Science ®Google Scholar
• Bosi E Ellis GC Wilson CA Fleck PR Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study Diabetes Obes Metab 2011 13 12 1088 1096 21733058
   PubMed Web of Science ®Google Scholar
• Pratley RE Reusch JE Fleck PR Wilson CA Mekki Q Alogliptin Study 009 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Curr Med Res Opin 2009 25 10 2361 2371 19650752
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Fleck PR Wilson CA Mekki Q Alogliptin Study 010 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 2008 31 12 2315 2317 18809631
   PubMed Web of Science ®Google Scholar
• Kutoh E Ukai Y Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial Endocrine 2012 41 3 435 441 22249941
   PubMed Web of Science ®Google Scholar
• Sakai Y Suzuki A Mugishima K Effects of alogliptin in chronic kidney disease patients with type 2 diabetes Intern Med 2014 53 3 195 203 24492687
   PubMed Web of Science ®Google Scholar
• Hattori S Sitagliptin reduces albuminuria in patients with type 2 diabetes Endocr J 2011 58 1 69 73 21206136
   PubMed Web of Science ®Google Scholar
• Hocher B Reichetzeder C Alter ML Renal and cardiac effects of DPP4 inhibitors – from preclinical development to clinical research Kidney Blood Press Res 2012 36 1 65 84 22947920
   PubMed Web of Science ®Google Scholar
• Nakamura Y Inagaki M Shimizu T Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study Nephron Clin Pract 2013 123 1–2 46 51 23774306
   PubMedGoogle Scholar
• Fujii Y Abe M Higuchi T The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis Expert Opin Pharmacother 2013 14 3 259 267 23289982
   PubMed Web of Science ®Google Scholar
• Li L Shen J Bala MM Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies BMJ 2014 348 g2366 24736555
   PubMed Web of Science ®Google Scholar
• Nesina™ (alogliptin) [package insert] Deerfield, IL Takeda Pharmaceuticals America, Inc 2013
   Google Scholar
• White WB Bakris GL Bergenstal RM EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome Am Heart J 2011 162 4 620 626. e1 21982652
   PubMed Web of Science ®Google Scholar
• Kapoor S Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects Diabetes Metab Syndr Obes 2012 5 121 123 22654521
   PubMedGoogle Scholar
• Eliasson B Möller-Goede D Eeg-Olofsson K Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study Diabetologia 2012 55 4 915 925 22237690
   PubMed Web of Science ®Google Scholar
• Shah Z Kampfrath T Deiuliis JA Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis Circulation 2011 124 21 2338 2349 22007077
   PubMed Web of Science ®Google Scholar
• Shah Z Pineda C Kampfrath T Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways Vascul Pharmacol 2011 55 1–3 2 9 21397040
   PubMed Web of Science ®Google Scholar
• Kazano™ (alogliptin and metformin HCl) [package insert] Deerfield, IL Takeda Pharmaceuticals America, Inc 2013
   Google Scholar
• Lipska KJ Bailey CJ Inzucchi SE Use of metformin in the setting of mild-to-moderate renal insufficiency Diabetes Care 2011 34 6 1431 1437 21617112
   PubMed Web of Science ®Google Scholar
• Oseni™ (alogliptin and pioglitazone) [package insert] Deerfield IL Takeda Pharmaceuticals America, Inc 2013
   Google Scholar
• Scheen AJ GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris) 2013 74 5–6 515 522 23570814
   PubMed Web of Science ®Google Scholar
• Andújar-Plata P Pi-Sunyer X Laferrère B Metformin effects revisited Diabetes Res Clin Pract 2012 95 1 1 9 22000494
   PubMed Web of Science ®Google Scholar
• Andukuri R Drincic A Rendell M Alogliptin: a new addition to the class of DPP-4 inhibitors Diabetes Metab Syndr Obes 2009 2 117 126 21437125
   PubMedGoogle Scholar
• Hanefeld M Pioglitazone and sulfonylureas: effectively treating type 2 diabetes Int J Clin Pract Suppl 2007 153 20 27 17594390
   PubMedGoogle Scholar
• Pratley RE McCall T Fleck PR Wilson CA Mekki Q Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies J Am Geriatr Soc 2009 57 11 2011 2019 19793357
   PubMed Web of Science ®Google Scholar